Atle Fund Management AB as of March 31, 2026
Portfolio Holdings for Atle Fund Management AB
Atle Fund Management AB holds 39 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Eli Lilly & Co. (LLY) | 8.7 | $27M | 40k | 675.83 | |
| Merck & Co (MRK) | 7.4 | $23M | 34k | 676.96 | |
| Thermo Fisher Scientific (TMO) | 4.7 | $14M | 23k | 628.64 | |
| Beone Medicines Ltd- Sponsored Ads (ONC) | 3.9 | $12M | 42k | 290.94 | |
| Johnson & Johnson (JNJ) | 3.9 | $12M | 92k | 129.29 | |
| Bridgebio Pharma (BBIO) | 3.8 | $12M | 111k | 106.80 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 3.6 | $11M | 23k | 485.90 | |
| Abbvie (ABBV) | 3.4 | $10M | 108k | 96.00 | |
| Stryker Corporation (SYK) | 3.1 | $9.6M | 27k | 356.99 | |
| Intuitive Surgical Com New (ISRG) | 3.0 | $9.4M | 71k | 133.30 | |
| Ionis Pharmaceuticals (IONS) | 3.0 | $9.4M | 28k | 337.20 | |
| Mirum Pharmaceuticals (MIRM) | 3.0 | $9.4M | 196k | 48.00 | |
| CVS Caremark Corporation (CVS) | 3.0 | $9.3M | 24k | 389.82 | |
| Revolution Medicines (RVMD) | 2.9 | $9.1M | 617k | 14.71 | |
| Boston Scientific Corporation (BSX) | 2.9 | $8.8M | 40k | 218.74 | |
| Amgen (AMGN) | 2.8 | $8.7M | 22k | 397.94 | |
| Edwards Lifesciences (EW) | 2.7 | $8.3M | 107k | 77.61 | |
| Alkermes SHS (ALKS) | 2.7 | $8.2M | 243k | 33.96 | |
| Incyte Corporation (INCY) | 2.6 | $8.0M | 51k | 156.98 | |
| Neurocrine Biosciences (NBIX) | 2.5 | $7.9M | 90k | 87.58 | |
| Gilead Sciences (GILD) | 2.3 | $7.2M | 48k | 149.20 | |
| Krystal Biotech (KRYS) | 2.2 | $6.8M | 38k | 180.79 | |
| AmerisourceBergen (COR) | 2.1 | $6.6M | 24k | 281.35 | |
| Irhythm Technologies (IRTC) | 2.0 | $6.3M | 22k | 280.43 | |
| Insmed Com Par $.01 (INSM) | 1.9 | $6.0M | 97k | 61.12 | |
| Newamsterdam Pharma Co Nv Ordinary Shares (NAMS) | 1.8 | $5.5M | 95k | 58.11 | |
| Celcuity (CELC) | 1.7 | $5.1M | 141k | 36.39 | |
| Abivax Sa Sponsored Ads (ABVX) | 1.5 | $4.8M | 32k | 151.43 | |
| Cardinal Health (CAH) | 1.5 | $4.8M | 109k | 43.87 | |
| Ideaya Biosciences (IDYA) | 1.3 | $4.0M | 31k | 128.85 | |
| Tango Therapeutics (TNGX) | 1.2 | $3.6M | 30k | 121.33 | |
| Spyre Therapeutics Com New (SYRE) | 1.1 | $3.5M | 63k | 55.56 | |
| Disc Medicine (IRON) | 1.0 | $3.2M | 107k | 29.73 | |
| Compass Therapeutics (CMPX) | 1.0 | $3.1M | 42k | 72.94 | |
| UnitedHealth (UNH) | 0.9 | $2.8M | 15k | 189.43 | |
| Dexcom Com New (DXCM) | 0.9 | $2.6M | 584k | 4.52 | |
| Bicara Therapeutics (BCAX) | 0.7 | $2.3M | 1.2M | 1.98 | |
| Soleno Therapeutics (SLNO) | 0.7 | $2.2M | 90k | 24.48 | |
| Pyxis Oncology Common Stock (PYXS) | 0.5 | $1.6M | 197k | 8.21 |
